Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of sitagliptin + atorvastatin vs atorvastatin in type 2 diabetes inadequately controlled on metformin
2011-003600-20Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline A1C at week 16. Started Nov 2011; status: terminated.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-003600-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003600-20.